Mechanisms of aryl hydrocarbon receptor control of eosinophilic esophagitis
- Institution
- CINCINNATI CHILDRENS HOSP MED CTR, OH
- Principal investigator
- Nurit P Azouz
- Funding
- $623K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMRAY Eosinophilic esophagitis (EoE) is an allergic disease of the esophagus partially mediated by epithelial barrier breach, resulting in harmless antigens penetrating the underlying tissues, encountering immune cells, and triggering allergic responses. The surge in allergy prevalence is often attributed to shifts in environmental conditions and western life style. The molecular mechanisms involved in how the environment elicits allergic diseases is an area of active research that is yet to be fully understood. The aryl hydrocarbon receptor (AHR) is an intracellular receptor responsive to various external stimuli, including dietary compounds, air toxicants, pharmacologic agents, microbiota metabolites and tryptophan metabolites. Our research has uncovered that AHR acts as a sensor molecule, capable of either maintaining epithelial homeostasis and barrier integrity, or initiating an innate immune response when exposed to diverse AHR ligands from different environmental sources. As a result, AHR can play a dual role in EoE, both protecting against and exacerbating EoE. We have shown that select AHR ligands induced protective transcriptional responses in esophageal epithelial cells. These responses counteract pathways involved in the development of type 2 immunity, including restoring barrier function and the deficiency of SPINK7, a crucial endogenous protease inhibitor, normally essential for averting EoE. These anti-inflammatory reactions rely on the activation of the transcription factor Ovo Like Zinc (OVOL1). Conversely, environmental factors such as enriched tryptophan diets can stimulate AHR, exacerbating esophageal inflammation in mice. In this study we aim to elucidate the mechanism through which AHR mediates its protective and detrimental reactions in response to divergent AHR ligands. We have established experimental platforms including the generation of AHR and OVOL1 deficient esophageal epithelial cell lines, mice with conditional depletion of Ahr and Ovol1 in the esophageal epithelium, experimental EoE murine models and three-dimensional human organotypic esophageal raft cultures to test the hypothesis that AHR drives differential esophageal epithelial responses, and the nature of the AHR ligands dictates the AHR dependent protective (barrier function) and detrimental (innate inflammation) outcomes. Successful completion of this study holds immediate translational significance, as it could pave the way for dietary adjustments, probiotics, and newly-approved AHR agonists which will offer potential avenues for interventions against EoE.
LOADING MOONBASE SCORE
Questions for CINCINNATI CHILDRENS HOSP MED CTR
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Cincinnati Childrens Hosp Med CtrNot yet scored
The role of serpins and LRP1 in the esophageal epithelium during eosinophilic esophagitis
Nurit P Azouz · $553K · 2024–2029
- NIH · Cincinnati Childrens Hosp Med Ctr54
Sirolimus TSC Epilepsy Prevention Study (STEPS) IND#145820 11/8/2019
Martina Bebin · $651K · 2021–2027
- NIH · Cincinnati Childrens Hosp Med Ctr48
Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) IND #152820 9/2/20
Michael Jordan · $530K · 2021–2027